- Home
- MDXH vs EPRX Comparison
MDXH vs EPRX Comparison
Compare MDXH & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- EPRX
- Stock Information
- Founded
- MDXH 2003
- EPRX 2011
- Country
- MDXH Belgium
- EPRX Canada
- Employees
- MDXH N/A
- EPRX N/A
- Industry
- MDXH
- EPRX
- Sector
- MDXH
- EPRX
- Exchange
- MDXH Nasdaq
- EPRX NYSE
- Market Cap
- MDXH 93.1M
- EPRX 109.7M
- IPO Year
- MDXH 2021
- EPRX N/A
- Fundamental
- Price
- MDXH $1.86
- EPRX $3.65
- Analyst Decision
- MDXH Strong Buy
- EPRX Strong Buy
- Analyst Count
- MDXH 2
- EPRX 1
- Target Price
- MDXH $7.00
- EPRX $9.00
- AVG Volume (30 Days)
- MDXH 58.0K
- EPRX 15.8K
- Earning Date
- MDXH 02-26-2025
- EPRX 03-04-2025
- Dividend Yield
- MDXH N/A
- EPRX N/A
- EPS Growth
- MDXH N/A
- EPRX N/A
- EPS
- MDXH N/A
- EPRX N/A
- Revenue
- MDXH $84,708,000.00
- EPRX N/A
- Revenue This Year
- MDXH $28.76
- EPRX N/A
- Revenue Next Year
- MDXH $19.91
- EPRX N/A
- P/E Ratio
- MDXH N/A
- EPRX N/A
- Revenue Growth
- MDXH 33.01
- EPRX N/A
- 52 Week Low
- MDXH $1.55
- EPRX $2.20
- 52 Week High
- MDXH $3.85
- EPRX $4.08
- Technical
- Relative Strength Index (RSI)
- MDXH 41.65
- EPRX N/A
- Support Level
- MDXH $1.82
- EPRX N/A
- Resistance Level
- MDXH $2.01
- EPRX N/A
- Average True Range (ATR)
- MDXH 0.09
- EPRX 0.00
- MACD
- MDXH 0.01
- EPRX 0.00
- Stochastic Oscillator
- MDXH 46.43
- EPRX 0.00
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.